Dr. Andrew Leber

Chief Development Officer

Andrew Leber, Ph.D. contributes deep knowledge of immunology, advanced computational modeling, data analytics, AI, and drug development to NImmune Biopharma. As the Chief Development Officer, he is responsible for assessing the therapeutic potential of lead immunoregulatory targets in autoimmune diseases. Dr. Leber’s expertise in immunometabolism helped advance our first-in-class asset for IBD, BT- 11, into clinical development. Dr. Leber obtained his B.S. in bioengineering and biomedical engineering from Pennsylvania State University and his Ph.D. in genetics, bioinformatics, and computational biology from Virginia Tech.